Cardiol Therapeutics Inc.
Support and Resistance Levels
Past performance
News About CRDL
All events for CRDL
All deals for CRDL
Financial Ratios
Financial Statements
CRDL vs Sector & Peers
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada. Website cardiolrx.com
Headquarters Oakville, ON, CA